Telix publishes investor presentation outlining radiopharmaceutical growth strategy and pipeline updates
PUBT · 06/01 05:48
Share
Listen to the news
- Telix outlined 16% quarter-on-quarter growth in Q1 2026 Precision Medicine sales to USD 186 million.
- Two FDA-cleared PSMA imaging agents now marketed across 22 countries; China NDA under NMPA review; Japan registration-enabling study underway.
- Glioma imaging agent Pixclara/Pixlumi flagged with a Sep. 11, 2026 PDUFA date; European MAA accepted.
- Renal mass imaging program advanced through two FDA Type A meetings; BLA resubmission in progress.
- Pipeline focus includes TLX591-Tx Phase 3 in PSMA+ mCRPC and TLX101-Tx pivotal recurrent GBM study; Precision Medicine growth framed at 20%-40% CAGR.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved